Literature DB >> 29375184

Hyperprolactinaemia.

Angela X Chen1, Morton G Burt1.   

Abstract

Entities:  

Keywords:  dopamine agonist; hyperprolactinaemia; prolactin; prolactinoma

Year:  2017        PMID： 29375184      PMCID： PMC5768604          DOI： 10.18773/austprescr.2017.060

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  9 in total

Review 1.  Clinical practice. Prolactinomas.

Authors:  Anne Klibanski
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

2.  Dopamine agonists and the risk of cardiac-valve regurgitation.

Authors:  René Schade; Frank Andersohn; Samy Suissa; Wilhelm Haverkamp; Edeltraut Garbe
Journal:  N Engl J Med       Date:  2007-01-04       Impact factor: 91.245

3.  The epidemiology of prolactinomas.

Authors:  Antonio Ciccarelli; Adrian F Daly; Albert Beckers
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 4.  Medication-induced hyperprolactinemia.

Authors:  Mark E Molitch
Journal:  Mayo Clin Proc       Date:  2005-08       Impact factor: 7.616

5.  Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.

Authors:  Niki Karavitaki; Gaya Thanabalasingham; Helena C A Shore; Raluca Trifanescu; Olaf Ansorge; Niki Meston; Helen E Turner; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

Review 6.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.

Authors:  Shlomo Melmed; Felipe F Casanueva; Andrew R Hoffman; David L Kleinberg; Victor M Montori; Janet A Schlechte; John A H Wass
Journal:  J Clin Endocrinol Metab       Date:  2011-02       Impact factor: 5.958

7.  Should macroprolactin be measured in all hyperprolactinaemic sera?

Authors:  T Joseph McKenna
Journal:  Clin Endocrinol (Oxf)       Date:  2009-03-06       Impact factor: 3.478

8.  A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.

Authors:  J Webster; G Piscitelli; A Polli; C I Ferrari; I Ismail; M F Scanlon
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245

9.  Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.

Authors:  Annamaria Colao; Antonella Di Sarno; Paolo Cappabianca; Carolina Di Somma; Rosario Pivonello; Gaetano Lombardi
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.